© 2011

Purinergic Regulation of Respiratory Diseases

  • Maryse Picher
  • Richard C. Boucher

Part of the Subcellular Biochemistry book series (SCBI, volume 55)

Table of contents

  1. Front Matter
    Pages i-xvii
  2. Eduardo R. Lazarowski, Juliana I. Sesma, Lucia Seminario, Charles R. Esther Jr., Silvia M. Kreda
    Pages 1-15
  3. Maryse Picher
    Pages 17-49
  4. Guilherme J. M. Garcia, Maryse Picher, Peiying Zuo, Seiko F. Okada, Eduardo R. Lazarowski, Brian Button et al.
    Pages 51-74
  5. Charles R. Esther Jr., Neil E. Alexis, Maryse Picher
    Pages 75-93
  6. Andreas Schmid, Lucy A. Clunes, Mathias Salathe, Pedro Verdugo, Paul Dietl, C. William Davis et al.
    Pages 95-138
  7. Albert van der Vliet, Peter F. Bove
    Pages 139-157
  8. Michael Koeppen, Francesco Di Virgilio, Eric T. Clambey, Holger K. Eltzschig
    Pages 159-193
  9. Linda F. Thompson, Maryse Picher, Michael R. Blackburn
    Pages 195-234
  10. Stephen Tilley, Jon Volmer, Maryse Picher
    Pages 235-276
  11. Back Matter
    Pages 277-280

About this book


We proudly present the first book to integrate all aspects of purinergic signaling in the respiratory system. The first chapters introduce basic notions of purinergic pharmacology and metabolism, which allows readers from all scientific backgrounds to fully grasp the importance of these signaling networks for airway defenses, including mucociliary clearance and inflammatory responses. Then, chapters are devoted to the groundbreaking discovery that chronic respiratory diseases, including asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD), present specific aberrances in purinergic signaling which essentially drive lung complications. The last chapters describe the animal models used to investigate purinergic signaling in respiratory diseases, and the therapeutic applications developed by the pharmaceutical industry based on receptor agonists/antagonists and metabolic correctors. This highly comprehensive manuscript constitutes an invaluable tool for beginners and experts to follow the rapidly evolving research field of purinergic signaling. Furthermore, the critical analysis of past clinical protocols should facilitate the identification of potent therapeutic targets, and provide a better understanding of the data acquired in current clinical trials.


Adenosine Asthma Chronic obstructive pulmonary disease (COPD) Ectonucleotidases Purinergic signaling

Editors and affiliations

  • Maryse Picher
    • 1
  • Richard C. Boucher
    • 2
  1. 1.and Treatment Center, Cystic Fibrosis Pulmonary Research and TUniversity of North CarolinaChapel Hill,USA
  2. 2.University of North Carolina- Cystic Fibrosis Pulmonary Research andCHAPEL HILLUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Consumer Packaged Goods